Epoetin Alfa Hexal

Country: European Union

Language: Italian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

epoetina alfa

Available from:

Hexal AG

ATC code:

B03XA01

INN (International Name):

epoetin alfa

Therapeutic group:

Preparazioni antianemiche

Therapeutic area:

Anemia; Kidney Failure, Chronic; Cancer

Therapeutic indications:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. Trattamento dell'anemia e riduzione del fabbisogno trasfusionale in pazienti adulti in chemioterapia per tumori solidi, linfoma maligno o mieloma multiplo e a rischio di trasfusione come valutato da stato generale del paziente (e. stato cardiovascolare, pre-esistente anemia all'inizio della chemioterapia).

Product summary:

Revision: 24

Authorization status:

autorizzato

Authorization date:

2007-08-27

Patient Information leaflet

                                78
B. FOGLIO ILLUSTRATIVO
79
FOGLIO ILLUSTRATIVO: INFORMAZIONI PER IL PAZIENTE
EPOETIN ALFA HEXAL 1.000 UI/0,5 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 2.000 UI/1 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 3.000 UI/0,3 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 4.000 UI/0,4 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 5.000 UI/0,5 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 6.000 UI/0,6 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 7.000 UI/0,7 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 8.000 UI/0,8 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 9.000 UI/0,9 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 10.000 UI/1 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 20.000 UI/0,5 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 30.000 UI/0,75 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
EPOETIN ALFA HEXAL 40.000 UI/1 ML SOLUZIONE INIETTABILE IN SIRINGA
PRERIEMPITA
Epoetina alfa
LEGGA ATTENTAMENTE QUESTO FOGLIO PRIMA DI USARE QUESTO MEDICINALE
PERCHÉ CONTIENE IMPORTANTI
INFORMAZIONI PER LEI.
-
Conservi questo foglio. Potrebbe aver bisogno di leggerlo di nuovo.
-
Se ha qualsiasi dubbio, si rivolga al medico, al farmacista o
all’infermiere.
-
Questo medicinale è stato prescritto soltanto per lei. Non lo dia ad
altre persone, anche se i
sintomi della malattia sono uguali ai suoi, perché potrebbe essere
pericoloso.
-
Se si manifesta un qualsiasi effetto indesiderato, compresi quelli non
elencati in questo foglio, si
rivolga al medico, al farmacista o all’infermiere. Vedere paragrafo
4.
CONTENUTO DI QUESTO FOGLIO
1.
Cos’è Epoetin alfa HEXAL e a cosa serve
2.
Cosa deve sapere prima di usare Epoetin alfa HEXAL
3.
Come usare Epoetin alfa HEXAL
4.
Possibili effetti indesiderati
5.
Come conservare Epoetin alfa HEXAL
6.
Contenuto della confezione e altre informazioni
1.
COS’È
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ALLEGATO I
RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO
2
1.
DENOMINAZIONE DEL MEDICINALE
Epoetin alfa HEXAL 1.000 UI/0,5 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 2.000 UI/1 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 3.000 UI/0,3 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 4.000 UI/0,4 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 5.000 UI/0,5 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 6.000 UI/0,6 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 7.000 UI/0,7 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 8.000 UI/0,8 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 9.000 UI/0,9 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 10.000 UI/1 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 20.000 UI/0,5 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 30.000 UI/0,75 mL soluzione iniettabile in siringa
preriempita
Epoetin alfa HEXAL 40.000 UI/1 mL soluzione iniettabile in siringa
preriempita
2.
COMPOSIZIONE QUALITATIVA E QUANTITATIVA
Epoetin alfa HEXAL 1.000 UI/0,5 mL soluzione iniettabile in siringa
preriempita
Ogni mL di soluzione contiene 2.000 UI di epoetina alfa*,
corrispondenti a 16,8 microgrammi per mL
Una siringa preriempita da 0,5 mL contiene 1.000 unità internazionali
(UI), corrispondenti a
8,4 microgrammi di epoetina alfa. *
Epoetin alfa HEXAL 2.000 UI/1 mL soluzione iniettabile in siringa
preriempita
Ogni mL di soluzione contiene 2.000 UI di epoetina alfa*,
corrispondenti a 16,8 microgrammi per mL
Una siringa preriempita da 1 mL contiene 2.000 unità internazionali
(UI), corrispondenti a
16,8 microgrammi di epoetina alfa. *
Epoetin alfa HEXAL 3.000 UI/0,3 mL soluzione iniettabile in siringa
preriempita
Ogni mL di soluzione contiene 10.000 UI di epoetina alfa*,
corrispondenti a 84,0 microgrammi per
mL
Una siringa preriempita da 0,3 mL contiene 3.000 unità internazionali
(UI), co
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-11-2023
Public Assessment Report Public Assessment Report Bulgarian 02-10-2018
Patient Information leaflet Patient Information leaflet Spanish 21-11-2023
Public Assessment Report Public Assessment Report Spanish 02-10-2018
Patient Information leaflet Patient Information leaflet Czech 21-11-2023
Public Assessment Report Public Assessment Report Czech 02-10-2018
Patient Information leaflet Patient Information leaflet Danish 21-11-2023
Public Assessment Report Public Assessment Report Danish 02-10-2018
Patient Information leaflet Patient Information leaflet German 21-11-2023
Public Assessment Report Public Assessment Report German 02-10-2018
Patient Information leaflet Patient Information leaflet Estonian 21-11-2023
Public Assessment Report Public Assessment Report Estonian 02-10-2018
Patient Information leaflet Patient Information leaflet Greek 21-11-2023
Public Assessment Report Public Assessment Report Greek 02-10-2018
Patient Information leaflet Patient Information leaflet English 21-11-2023
Public Assessment Report Public Assessment Report English 02-10-2018
Patient Information leaflet Patient Information leaflet French 21-11-2023
Public Assessment Report Public Assessment Report French 02-10-2018
Patient Information leaflet Patient Information leaflet Latvian 21-11-2023
Public Assessment Report Public Assessment Report Latvian 02-10-2018
Patient Information leaflet Patient Information leaflet Lithuanian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-11-2023
Public Assessment Report Public Assessment Report Lithuanian 02-10-2018
Patient Information leaflet Patient Information leaflet Hungarian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 21-11-2023
Public Assessment Report Public Assessment Report Hungarian 02-10-2018
Patient Information leaflet Patient Information leaflet Maltese 21-11-2023
Public Assessment Report Public Assessment Report Maltese 02-10-2018
Patient Information leaflet Patient Information leaflet Dutch 21-11-2023
Public Assessment Report Public Assessment Report Dutch 02-10-2018
Patient Information leaflet Patient Information leaflet Polish 21-11-2023
Public Assessment Report Public Assessment Report Polish 02-10-2018
Patient Information leaflet Patient Information leaflet Portuguese 21-11-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 21-11-2023
Public Assessment Report Public Assessment Report Portuguese 02-10-2018
Patient Information leaflet Patient Information leaflet Romanian 21-11-2023
Public Assessment Report Public Assessment Report Romanian 02-10-2018
Patient Information leaflet Patient Information leaflet Slovak 21-11-2023
Public Assessment Report Public Assessment Report Slovak 02-10-2018
Patient Information leaflet Patient Information leaflet Slovenian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 21-11-2023
Public Assessment Report Public Assessment Report Slovenian 02-10-2018
Patient Information leaflet Patient Information leaflet Finnish 21-11-2023
Public Assessment Report Public Assessment Report Finnish 02-10-2018
Patient Information leaflet Patient Information leaflet Swedish 21-11-2023
Public Assessment Report Public Assessment Report Swedish 02-10-2018
Patient Information leaflet Patient Information leaflet Norwegian 21-11-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 21-11-2023
Patient Information leaflet Patient Information leaflet Icelandic 21-11-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 21-11-2023
Patient Information leaflet Patient Information leaflet Croatian 21-11-2023
Public Assessment Report Public Assessment Report Croatian 02-10-2018

Search alerts related to this product